AstraZeneca’s lung cancer combo cut progression-or-death risk by 45% vs chemo. Europe and Japan review it.
AstraZeneca and HUTCHMED announced regulatory filings for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) in Europe and Japan, following a US FDA submission. The combination showed a 45% reduction in progression-or-death risk vs. chemo in a Phase III trial for NSCLC with MET overexpression or amplification. The EMA and MHLW accepted the applications for review, supported by positive SAFFRON trial data presented at ESMO 2026 and published in The New England Journal of Medicine.
How this was made
The 30-second read
Why it matters
Regulatory acceptance signals a potential new treatment option, influencing investor sentiment toward both companies.
Market read
First report of regulatory review acceptance for a major oncology combo, likely to move AZN and HCM stocks.
What to watch
Competition from other MET inhibitors and pricing negotiations.
Background
AstraZeneca and Hutchmed co‑developed ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) for MET‑positive NSCLC.
Ticker impact
AstraZeneca's regulatory filings for the ORPATHYS/TAGRISSO lung cancer combo were accepted for review in Europe and Japan.
likely upward pressure as market prices in possible approval.
First report of EMA and MHLW review acceptance for a high‑impact oncology combo.
Hutchmed announced that its ORPATHYS/TAGRISSO combination filings were accepted for review in Europe and Japan.
likely upward pressure as investors anticipate future revenue.
First disclosure of regulatory review acceptance for its co‑developed drug.
Market effects
strengthens the lung cancer/oncology therapeutic sector.
adds pipeline momentum in Europe and Japan markets.
affects global oncology drug development landscape.
Counterpoint
If regulatory review stalls, the hype could reverse quickly.
Key entities
- CompanyAstraZeneca
Global pharma firm seeking EMA and MHLW approval.
- CompanyHutchmed
Chinese biopharma partner in the combo therapy.
